Valneva Announces Drawdown of Further €10 million from its Existing European Investment Bank Loan

Valneva SE (“Valneva” or “the Company”), a biotech company developing and commercializing vaccines for infectious diseases with major unmet needs, announces today that it has drawn down a further €10 million from  its existing European Investment Bank (EIB) loan facility. The €25 million loan was granted to the Company by the EIB in July 2016.

Read more